Compare McKesson Corporation (MCK) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs New York Times Co — how do they compare? McKesson Corporation trades at $885.2 (market cap $105.14B), while New York Times Co trades at $63.75 (market cap $10.28B). The key difference: McKesson Corporation is far larger — about 10.2× New York Times Co's market cap, and New York Times Co pays the higher dividend (1.44%). Which is the better fit depends on your goals.
| MCK | NYT | |
|---|---|---|
Market Cap | $105.14B | $10.28B |
Sector | Health | Media |
52-Week High | $995.69 | $85.86 |
52-Week Low | $659.01 | $54.66 |
Enterprise Value | $111.67B | $9.67B |
Dividend Yield | 0.42% | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
The New York Times (NYT) stock trades at $64.21, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth remains steady, reaching $2.82 billion in 2025, with net income margins improving to 12.17%. The company faces headwinds from slowing digital subscriber growth, as highlighted in recent quarterly reports, but maintains strong profitability and cash flow generation.
Outlook is mixed; valuation appears full with a P/E of 26.55, yet analyst consensus targets $77.50 suggest upside. Key risks include subscriber growth moderation and competitive pressures. The stock offers a dividend yield with the next payment scheduled for July 23, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
